Nephro Care India Aims to Raise Rs. 35-40 Crore from Upcoming IPO
Written by Arushi Sharma
Nephro Care India is set to raise funds through an IPO to establish a multi-speciality hospital in Kolkata.
Nephro Care India, a leading healthcare provider specializing in nephrology, has announced plans to raise Rs. 35-40 crore through an initial public offering (IPO). The move, subject to approval from the NSE Emerge platform, is a strategic effort to expand its operations across India.
The net proceeds from the IPO will be directed towards establishing a multi-speciality hospital named ‘Vivacity Multi Speciality Hospital’ in Madhyamgram, Kolkata, West Bengal. The remaining capital will be allocated for general corporate purposes.
The new hospital, a unit of Nephro Care, is set to feature 100 inpatient beds, including a 30-bed critical care unit with ICU, HDU, RTU, and NICU facilities. Vivacity will offer treatment services in various disciplines, including cardiology, medical oncology, gastroenterology, gynecology, and an advanced renal transplant unit.
Key Highlights of the IPO
Fresh Issuance: The IPO will consist of a fresh issuance of 45.84 lakh equity shares with a face value of Rs.10 each.
Book Running Lead Manager: Corporate Capital Ventures will act as the Book Running Lead Manager, with Bigshare Services serving as the Registrar to the offer. Corporate Capital Ventures has a track record of managing successful SME IPOs, including those of Trust Fintech, Creative Graphics, Alpex Solar, Esconet Technologies, Rockingdeals, Accent Microcell, Oriana Power, Droneacharya, and Crayons Advertising.
Financial Performance: Nephro Care India Limited (NCIL) has shown significant financial growth. The company posted a revenue of Rs. 19.90 crore and a profit (PAT) of Rs. 3.4 crore in the first nine months of FY 2023-24, compared to a revenue of Rs. 17.09 crore and a profit (PAT) of Rs. 1.94 crore in FY 2022-23.
Founded in 2014 by Dr. Pratim Sengupta, a renowned nephrologist in India, Nephro Care has been dedicated to providing comprehensive medical services for kidney patients. The upcoming IPO marks a significant milestone in the company’s journey, poised to enhance its capacity to serve more patients and expand its healthcare footprint.